home.social

#insmed — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #insmed, aggregated by home.social.

  1. Yonhap Infomax News @[email protected] ·

    Jefferies maintains its 'Buy' rating on Insmed, citing strong expectations for Phase 2 trial results of its PAH treatment TPIP, which could challenge current standard therapies.
    #YonhapInfomax #Insmed #Jefferies #TPIP #Phase2Trial #PulmonaryVascularResistance #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #insmed #jefferies #tpip #phase2trial #pulmonaryvascularresistance
  2. Yonhap Infomax News @[email protected] ·

    Jefferies maintains its 'Buy' rating on Insmed, citing strong expectations for Phase 2 trial results of its PAH treatment TPIP, which could challenge current standard therapies.
    #YonhapInfomax #Insmed #Jefferies #TPIP #Phase2Trial #PulmonaryVascularResistance #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #insmed #jefferies #tpip #phase2trial #pulmonaryvascularresistance
  3. Yonhap Infomax News @[email protected] ·

    Jefferies maintains its 'Buy' rating on Insmed, citing strong expectations for Phase 2 trial results of its PAH treatment TPIP, which could challenge current standard therapies.
    #YonhapInfomax #Insmed #Jefferies #TPIP #Phase2Trial #PulmonaryVascularResistance #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #insmed #jefferies #tpip #phase2trial #pulmonaryvascularresistance
  4. Yonhap Infomax News @[email protected] ·

    Jefferies maintains its 'Buy' rating on Insmed, citing strong expectations for Phase 2 trial results of its PAH treatment TPIP, which could challenge current standard therapies.
    #YonhapInfomax #Insmed #Jefferies #TPIP #Phase2Trial #PulmonaryVascularResistance #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #stockmarket #bonds #securities #banking #financialmarkets #economics
  5. Yonhap Infomax News @[email protected] ·

    Jefferies maintains its 'Buy' rating on Insmed, citing strong expectations for Phase 2 trial results of its PAH treatment TPIP, which could challenge current standard therapies.
    #YonhapInfomax #Insmed #Jefferies #TPIP #Phase2Trial #PulmonaryVascularResistance #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #insmed #jefferies #tpip #phase2trial #pulmonaryvascularresistance